ArticleFrontiers in cardiovascular medicine2026
Triglyceride-glucose index and the progression of chronic obstructive pulmonary disease, panvascular disease, and multimorbidity: a prospective cohort study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic obstructive pulmonary disease (COPD) and panvascular disease (PD) are often driven by shared risk factors. We aimed to investigate the longitudinal association of triglyceride-glucose (TyG) index with incidence of COPD, PD, and their multimorbidity. Methods: Our study used data from the UK Biobank, a population-based prospective study. Cox proportional hazards regression was used to evaluate the association between TyG index and the risk of incident COPD, panvascular disease, and their Multimorbidity. Multistate models (MSMs) were used to evaluate the longitudinal progression from healthy to incident COPD or PD, and ultimately to multimorbidity, across TyG index quartiles. Results: Among the 296,818 participants included in the final analysis, the TyG index was associated with higher incidence of COPD and PD. Each 1-SD increase in TyG index was associated with a 9% higher risk of PD (HR 1.09, 95% CI 1.05-1.12). These associations were more pronounced among females. In multistate analyses, compared with the lowest quartile, women in the highest TyG quartile had greater risks of progression from baseline to COPD (HR 1.22, 95% CI 1.04-1.43), baseline to PD (HR 1.29, 95% CI 1.19-1.39), COPD to multimorbidity (HR 2.11, 95% CI 1.32-3.37), and PD to multimorbidity (HR 3.67, 95% CI 2.00-6.72). For males, a higher TyG index was protective against COPD incidence (HR 0.79, 95% CI 0.68-0.93) but increased PD risk (HR 1.18, 95% CI 1.09-1.26), whereas no significant associations were found for other transitions. Conclusions: Elevated TyG index was associated with incident COPD and PD, while the association with multimorbidity was attenuated after full adjustment in the overall cohort. In multistate analyses, stronger and more consistent associations were observed in women, particularly for progression from single disease to multimorbidity. The TyG index may serve as a metabolic indicator that helps identify women at elevated risk and may inform targeted prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.